Moderna, Inc. (MRNA) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 34 days, typically, give or take 6 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Fri, Nov 6, 2026before open 37 8-K
Q2 FY2026Fri, Jul 31, 2026before open 31 8-K
Q1 FY2026Fri, May 1, 2026before open 31 8-K
Q4 FY2025Fri, Feb 13, 2026before open 44 8-K
Q3 FY2025Thu, Nov 6, 2025before open 37 8-K
Q2 FY2025Fri, Aug 1, 2025before open 32 8-K
Q1 FY2025Thu, May 1, 2025before open 31 8-K
Q4 FY2024Fri, Feb 14, 2025before open 45 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38 Increases 2026 expected revenue growth to 15%–25%, exceeding the previous expectation of up to 10% growth Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate Increases 2026 expected ending cash balance to $8.1–$8.3 billion Highlights positive Phase 3 data for intismeran and U.S. FDA approval of mFLUSIVA, the Company's fifth approved produ" exhibit
Q3 FY2026 "“Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet." exhibit
Q3 FY2026 "Cost of sales increased by 54% compared to the same period in 2025, primarily driven by higher product sales volume and other manufacturing-related costs. 1 Research and Development Expenses: Research and development expenses for the third quarter of 2026 were $583 million, a 27% decrease compared to the same period in 2025, primarily driven by lower clinical development costs following the completion and wind-down of certain late-stage studies in the Company's infectious disease portfolio, as well as continued cost efficiencies across the organization." exhibit
Q3 FY2026 "The increase primarily reflected $2.6 billion in net proceeds from the issuance of convertible notes and related capped call transactions, partially offset by the $950 million payment related to the litigation settlement announced in the first quarter of 2026, and cash used in operations, including the seasonal working capital impact from third-quarter product sales, the majority of which remained uncollected at quarter-end. 2026 Financial Framework Revenue: The Company now expects total revenue growth of 15% to 25% in 2026, exceeding its previous outlook of up to 10% growth." exhibit
Q3 FY2026 "Moderna continues to expect approximately half of its 2026 revenue to come from the United States and half from international markets." exhibit
Q2 FY2026 "Document Exhibit 99.1 Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate and improves expected 2026 year-end cash balance to $4.7 - 5.2 billion Anticipates potential approval of Moderna's fifth product with the August 5th PDUFA date for mFLUSIVA, the Company's seasonal influenza vaccine candidate Announc" exhibit
Q2 FY2026 ""The second quarter marked another period of strong execution for Moderna as we advanced our pipeline and strengthened our financial profile with an improved 2026 operating expense outlook," said Stéphane Bancel, Chief Executive Officer of Moderna." exhibit
Q2 FY2026 ""In the second half of 2026, we are preparing for the potential approval of mFLUSIVA in the U.S., which would be our fifth approved product, and continue to anticipate important pivotal readouts for our intismeran in melanoma and propionic acidemia programs." Commercial Updates During the second quarter, Moderna continued to advance its multi-year revenue growth strategy by executing on strategic partnerships and key approvals." exhibit
Q2 FY2026 "Cost of sales decreased by 22% compared to the same period in 2025, primarily reflecting lower unutilized manufacturing capacity costs resulting from continued manufacturing productivity improvements and operational efficiencies." exhibit
Q2 FY2026 "The Company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026. 2026 Financial Framework Revenue: The Company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MRNA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MRNA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

MRNA earnings date badge

HTML

<a href="https://veritasdata.dev/company/MRNA/"><img src="https://veritasdata.dev/embed/MRNA.svg" alt="MRNA earnings date" width="240" height="56"></a>

Markdown

[![MRNA earnings date](https://veritasdata.dev/embed/MRNA.svg)](https://veritasdata.dev/company/MRNA/)

Script

<script async src="https://veritasdata.dev/embed/MRNA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MRNA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.